| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10052260 | The Journal of Urology | 2005 | 5 Pages |
Abstract
These data provide evidence to support PSA velocity greater than 1.5 ng/ml yearly as a surrogate end point for PCSM in patients with nonmetastatic, hormone refractory prostate cancer. Enrolling these men onto clinical trials evaluating the impact of chemotherapy on time to bone metastases and PCSM is warranted.
Related Topics
Health Sciences
Medicine and Dentistry
Nephrology
Authors
ANTHONY V. D'AMICO, JUDD MOUL, PETER R. CARROLL, LEON SUN, DEBORAH LUBECK, MING-HUI CHEN,